Nephrology Dialysis Transplantation 2006 21(6):1745; doi:10.1093/ndt/gfl294
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gadoliniuma specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
Nephrol Dial Transplant April 2006; 21: 11041108
The author would like to apologize for the error published in the article.
After personal communication with the radiologists the administered Gd-contained contrast agent was documented in the MR examination reports of the mentioned nine patients incompletely and inexactly as GdDTPA by themselves. There is solely one MR contrast agent used in the described observation period: GdDTPABMA. Therefore, all mentioned nine patients received GdDTPABMA and not GdDTPA.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
G. Roditi MRI contrast agent safety in renal impairment Clin Risk, March 1, 2009; 15(2): 47 - 53. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
